Cagrilintide is a synthetic 37-amino-acid peptide analogue of human amylin, engineered with sequence modifications to reduce fibril formation and a fatty acid chain for extended duration of action. As a dual amylin and calcitonin receptor agonist (DACRA), it activates AMY1, AMY2, AMY3, and calcitonin receptors. This pathway differs from GLP-1 receptor agonists. Natural amylin is co-secreted with insulin by pancreatic beta cells and helps signal satiety, slow gastric emptying, and suppress post-meal glucagon. Cagrilintide is studied both as monotherapy and, more prominently, in fixed-dose combination with semaglutide under the name CagriSema.
How Cagrilintide Works
Cagrilintide acts on amylin receptors in the brain, particularly areas involved in meal termination and appetite control. This mechanism is complementary to GLP-1 pathways.
In clinical research, cagrilintide has demonstrated dose-dependent effects on body weight reduction through reduced food intake. Phase 2 monotherapy data in adults with overweight or obesity showed mean weight loss ranging from approximately 6.0% to 10.8% over 26 weeks across doses up to 4.5 mg, compared with about 3.0% for placebo. The molecule’s long-acting design supports once-weekly subcutaneous administration. When paired with semaglutide in CagriSema, the combination targets two distinct satiety pathways, which researchers investigate for additive effects on weight and glycemic outcomes.
Cagrilintide Clinical Trial Results
Phase 3 programs such as REDEFINE and REIMAGINE have evaluated cagrilintide alone and in combination. Results focus on body weight change, HbA1c, and safety in adults with overweight, obesity, or type 2 diabetes.
In the REDEFINE 1 trial involving adults with overweight or obesity, cagrilintide monotherapy at 2.4 mg weekly produced about 11.8% mean weight loss over 68 weeks versus roughly 2.3% with placebo. The CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) achieved higher average reductions, reported in the range of 20–22.7% depending on the estimand. REDEFINE 2 examined adults with overweight or obesity and type 2 diabetes; once-weekly CagriSema at 2.4 mg each led to an estimated mean body weight change of −13.7% at week 68 compared with −3.4% for placebo. A higher proportion of participants reached weight loss thresholds of 5%, 10%, 15%, and 20%, and more achieved HbA1c of 6.5% or lower.
REIMAGINE trials further assessed CagriSema across stages of type 2 diabetes. In REIMAGINE 1, CagriSema 2.4/2.4 mg reduced HbA1c by about 1.8% and weight by 13.8% versus placebo over 40 weeks in injectable-naive adults. REIMAGINE 2 showed superior HbA1c and weight reductions compared with semaglutide or cagrilintide alone. REIMAGINE 3 evaluated add-on use to basal insulin, with HbA1c reductions of approximately 2.1–2.3% and weight loss of 10–12%. Gastrointestinal adverse events were the most common, typically mild to moderate and transient. Cagrilintide and CagriSema remain investigational and are not approved for use outside clinical trials.
Cagrilintide vs Semaglutide and Other Agents
Cagrilintide is not a GLP-1 receptor agonist. It targets amylin receptors, while semaglutide targets the GLP-1 receptor. The two are studied together because their mechanisms are complementary. Head-to-head and combination data from REIMAGINE and related programs show that CagriSema often produced greater weight and glycemic effects than either component alone in the studied populations. Comparisons with other agents, such as certain doses of tirzepatide, have also been reported in select trials. All findings apply to the specific trial populations, doses, and durations examined.
Current Development Status of Cagrilintide
Cagrilintide is not approved by regulatory authorities for any indication. Novo Nordisk submitted a new drug application for the CagriSema combination for weight management in December 2025. Review timelines and potential approval decisions remain pending as of the latest available information. Ongoing and completed phase 3 trials continue to generate data on efficacy, safety, and different patient groups, including those with type 2 diabetes on various background therapies. Research focuses on once-weekly subcutaneous dosing, typically at 1.0 mg or 2.4 mg levels for the combination. Individuals interested in this area of research should consult qualified healthcare professionals and refer to official trial registries or regulatory updates for the most current status.
Key Considerations for Cagrilintide Research
Clinical studies consistently report that gastrointestinal side effects are the most frequent adverse events associated with cagrilintide and CagriSema. These events are generally mild or moderate and tend to decrease over time. Hypoglycemia rates have been low in the reported trials when used as studied. Because cagrilintide is investigational, no commercial product is available, and it cannot be prescribed outside approved clinical research settings. Information on this page summarizes publicly reported trial data and is intended for educational purposes regarding ongoing scientific investigation into amylin-based approaches for weight management and type 2 diabetes.





Reviews
There are no reviews yet.